MY162344A - Probiotic composition for use in the treatment of bowel inflammation - Google Patents

Probiotic composition for use in the treatment of bowel inflammation

Info

Publication number
MY162344A
MY162344A MYPI2012003332A MYPI2012003332A MY162344A MY 162344 A MY162344 A MY 162344A MY PI2012003332 A MYPI2012003332 A MY PI2012003332A MY PI2012003332 A MYPI2012003332 A MY PI2012003332A MY 162344 A MY162344 A MY 162344A
Authority
MY
Malaysia
Prior art keywords
treatment
probiotic composition
bowel inflammation
cect
lactobacillus plantarum
Prior art date
Application number
MYPI2012003332A
Other languages
English (en)
Inventor
Mazo Jordi Espadaler
Castellana Jordi Cuñé
Original Assignee
Ab-Biotics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab-Biotics S A filed Critical Ab-Biotics S A
Publication of MY162344A publication Critical patent/MY162344A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/41—Pediococcus
    • A23V2400/413—Acidilactici
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI2012003332A 2010-01-28 2011-01-27 Probiotic composition for use in the treatment of bowel inflammation MY162344A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29911610P 2010-01-28 2010-01-28
EP10151998 2010-01-28

Publications (1)

Publication Number Publication Date
MY162344A true MY162344A (en) 2017-06-15

Family

ID=42243204

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012003332A MY162344A (en) 2010-01-28 2011-01-27 Probiotic composition for use in the treatment of bowel inflammation

Country Status (19)

Country Link
US (2) US20130101566A1 (enExample)
EP (1) EP2528610B1 (enExample)
JP (1) JP5777640B2 (enExample)
KR (1) KR101840239B1 (enExample)
CN (1) CN102905712B (enExample)
AU (1) AU2011209407B2 (enExample)
BR (1) BR112012018813B1 (enExample)
CA (1) CA2787544C (enExample)
CL (1) CL2012002062A1 (enExample)
CO (1) CO6511276A2 (enExample)
ES (1) ES2437940T3 (enExample)
MX (1) MX2012008817A (enExample)
MY (1) MY162344A (enExample)
PH (1) PH12012501540A1 (enExample)
PL (1) PL2528610T3 (enExample)
RU (1) RU2563525C2 (enExample)
UA (1) UA109123C2 (enExample)
WO (1) WO2011092261A1 (enExample)
ZA (1) ZA201205683B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
WO2012169842A2 (ko) * 2011-06-10 2012-12-13 (주)아모레퍼시픽 차나무 잎에서 분리한 신규 락토바실러스 플란타룸
JP5995593B2 (ja) * 2012-08-02 2016-09-21 丸善製薬株式会社 抗炎症剤
WO2014096901A1 (en) * 2012-12-18 2014-06-26 Compagnie Gervais Danone Strain of bifidobacterium animalis ssp. animalis
CN105263343B (zh) * 2013-04-08 2019-03-08 N·V·努特里奇亚 含有巯基蛋白酶抑制剂的发酵营养组合物
SI24570A (sl) 2013-12-23 2015-06-30 Medis D.O.O. Novi sevi rodu Lactobacillus in njihova uporaba
HK1225637A1 (zh) * 2014-02-28 2017-09-15 株式会社明治 功能性消化道障碍预防和/或改善剂
US10967013B2 (en) * 2014-04-23 2021-04-06 National Yang-Ming University Lactic acid bacterium for prophylaxis or treatment of a stress-induced disorder and a composition containing the same
US10188684B2 (en) * 2015-04-20 2019-01-29 National Yang-Ming University Method for preventing or treating functional gastrointestinal disorder by lactic acid bacterium
WO2016083450A2 (en) * 2014-11-25 2016-06-02 Stichting Top Institute Food And Nutrition New probiotic and new biomarker
BR112017011078B1 (pt) * 2014-11-28 2021-05-11 Anagenix Ip Limited usos de uma composição preparada a partir de kiwi ouro seco
US10195237B2 (en) * 2015-03-16 2019-02-05 Imagilin Technology Llc Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics
US10946050B2 (en) 2015-03-16 2021-03-16 Imagilin Technology Llc Compositions comprising probiotics and methods of use thereof
MA41010B1 (fr) * 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US10857190B2 (en) 2015-10-06 2020-12-08 Albert Einstein College Of Medicine Microbial hyperswarmers and uses thereof
RU2752157C2 (ru) 2017-01-31 2021-07-23 Юниверсити-Индастри Кооперейшн Груп Оф Кюн Хее Юниверсити Новые молочнокислые бактерии и их применение
KR102464397B1 (ko) * 2017-09-15 2022-11-08 (주)아모레퍼시픽 락토바실러스 플란타룸을 포함하는 위장관 질환의 예방 및 개선용 조성물
MX420836B (es) * 2018-02-02 2025-02-10 Kobiolabs Inc Cepa lactobacillus plantarum kbl396 y uso de la misma.
US11504408B2 (en) * 2018-03-15 2022-11-22 University Of Southern California Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology
AR115757A1 (es) * 2018-07-13 2021-02-24 Cj Cheiljedang Corp Composición que comprende la cepa cjlp475 de lactobacillus plantarum y la cepa cjlp17 de lactobacillus plantarum y el uso de la misma
KR102118343B1 (ko) * 2018-07-13 2020-06-03 롯데푸드 주식회사 장 도달력이 우수하고 장내 염증 예방 효과를 가지는 우유와 발효유
KR102036275B1 (ko) * 2018-10-02 2019-10-24 서울대학교 산학협력단 항-염증 활성이 우수한 페디오코커스 악시딜락티시 ldtm 5201 신균주(kctc 13563bp)
KR102038695B1 (ko) * 2018-10-30 2019-10-30 주식회사 종근당바이오 프로바이오틱스를 유효성분으로 포함하는 알코올성 장손상 예방 또는 치료용 조성물
US20220054561A1 (en) * 2018-12-14 2022-02-24 The University Of North Carolina At Chapel Hill Lachnospiraceae mitigates against radiation-induced hematopoietic/gastrointestinal injury and death, and promotes cancer control by radiation
KR102094415B1 (ko) * 2018-12-17 2020-03-30 강원대학교산학협력단 프로바이오틱 활성 및 항균활성을 갖는 페디오코커스 애시디락티시 균주
WO2021125822A1 (ko) * 2019-12-17 2021-06-24 한국 한의학 연구원 페디오코쿠스 이노피나투스를 유효성분으로 포함하는 숙취해소용 조성물
WO2022171304A1 (en) * 2021-02-12 2022-08-18 Ab-Biotics, S.A. Probiotic composition for the treatment of covid-19
JPWO2023176849A1 (enExample) 2022-03-17 2023-09-21
CN114921351B (zh) * 2022-05-06 2023-06-13 大连工业大学 一株具有益生功能的毕赤酵母菌dpuy-f1及在缓解结肠炎症状中的应用
CN116083277B (zh) * 2022-09-17 2024-02-13 浙江大学 具有缓解溃疡性结肠炎功效的乳酸片球菌zjuids13及其应用
KR20240102112A (ko) * 2022-12-23 2024-07-03 주식회사 씨티씨바이오 대장염 예방 또는 치료활성 및 장내 유해균에 항균활성을 지닌 락토바실러스 및 그의 용도
KR102803865B1 (ko) * 2023-07-31 2025-05-09 전라남도 사료첨가제 및 이를 포함하는 사료 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463796B (sv) 1988-03-09 1991-01-28 Carl Erik Albertsson Foerfarande foer framstaellning av en naeringskomposition och daervid framstaelld naeringskomposition
SE469875C (sv) 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
SE9501056D0 (sv) 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
FR2813790B1 (fr) * 2000-09-11 2004-03-12 Dolisos Lab Preparations pharmaceutiques contenant des extraits d'isoflavone de soja et des micro-organismes probiotiques
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
EP1633378A2 (en) * 2003-06-13 2006-03-15 N.V. Nutricia Pediocin-producing pediococci
KR101095712B1 (ko) * 2003-08-21 2011-12-20 오츠카 세이야쿠 가부시키가이샤 점막 면역 부활 작용을 갖는 유산균
EP1714660A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
AT501919B1 (de) * 2005-06-14 2008-09-15 Erber Ag Probiotischer, gesundheits- bzw. leistungsfördernder futtermittel- und/oder trinkwasserzusatz für tiere sowie seine verwendung
SI1951272T1 (sl) * 2005-10-06 2016-10-28 Probi Ab Uporaba lactobacillus za zdravljenje virusnih infekcij
DE602006017423D1 (de) * 2005-11-14 2010-11-18 Unilever Nv Essbares produkt, das ginseng-polysaccharide und gesunde bakterien enthält
US20070298013A1 (en) * 2006-06-23 2007-12-27 Altman Jay A Animal Nutritional Supplement and Method
JP2008013534A (ja) * 2006-07-07 2008-01-24 Health Vision:Kk ペット用プロバイオティクス製品
CN102006788A (zh) * 2008-03-14 2011-04-06 雀巢产品技术援助有限公司 合益素混合物
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
US8298526B2 (en) * 2010-06-02 2012-10-30 Genmont Biotech Inc. Lactobacillus strain, composition and use thereof for improving the syndrome of diabetes and complication thereof
WO2015021530A1 (en) * 2013-08-12 2015-02-19 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules

Also Published As

Publication number Publication date
PL2528610T3 (pl) 2014-02-28
WO2011092261A1 (en) 2011-08-04
CA2787544A1 (en) 2011-08-04
MX2012008817A (es) 2012-11-23
UA109123C2 (uk) 2015-07-27
US10155015B2 (en) 2018-12-18
CN102905712A (zh) 2013-01-30
EP2528610B1 (en) 2013-11-13
JP5777640B2 (ja) 2015-09-09
AU2011209407B2 (en) 2014-02-27
AU2011209407A1 (en) 2012-09-20
KR20130002372A (ko) 2013-01-08
PH12012501540A1 (en) 2012-10-22
KR101840239B1 (ko) 2018-03-20
BR112012018813B1 (pt) 2020-12-08
ES2437940T3 (es) 2014-01-15
EP2528610A1 (en) 2012-12-05
RU2012136615A (ru) 2014-03-10
CO6511276A2 (es) 2012-08-31
US20130101566A1 (en) 2013-04-25
RU2563525C2 (ru) 2015-09-20
BR112012018813A2 (pt) 2017-06-20
US20160220620A1 (en) 2016-08-04
ZA201205683B (en) 2013-08-28
JP2013517784A (ja) 2013-05-20
CL2012002062A1 (es) 2013-10-04
CA2787544C (en) 2019-07-09
CN102905712B (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
PH12012501540A1 (en) Probiotic composition for use in the treatment of bowel inflammation
WO2012047631A3 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
IL246293B (en) New preparations and methods for the treatment of vaccine-related diseases
MX348611B (es) Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
IN2012DN01638A (enExample)
PT2626076T (pt) Utilizações terapêuticas de lactobacillus salivarus ls01 22775
PH12013500441A1 (en) Materials and methods for improving gastrointestinal function
UA107089C2 (xx) Штами lactobacillus plantarum як гіпохолестеринемічні агенти
UA107573C2 (xx) LACTOBACILLUS JOHNSONII La1 NCC533 (CNCM I-1225) І ІМУННІ РОЗЛАДИ
MX346458B (es) Composicion probiotica para la salud bucal.
PL2457992T3 (pl) Nowa bakteria Lactobacillus plantarum i kompozycja ją zawierająca
EA201690147A1 (ru) Пероральные композиции
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
UA113399C2 (xx) Штам непатогенної грамнегативної бактерії та його застосування в дерматології
MY161197A (en) Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
ZA201804863B (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
HUE042643T2 (hu) Lactobacillus reuteri ATCC PTA 6475 csontveszteség
EA201291440A1 (ru) Пробиотические штаммы для применения при повышении трансэпителиального сопротивления
PH12012501963A1 (en) Compositions and methods for the diagnosis and treatment of tumor
BR112012018805A2 (pt) motor
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
WO2011151395A3 (en) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
GB201018154D0 (en) Method of treatment
WO2011139254A3 (en) Pharmaceutical formulations compising cefuroxime axetil
HK1147174A (en) Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome